Funded by the Center for Medicare and Medicaid Innovation, an overarching goal of the MOM model is to improve provider comfort and competency in treating pregnant and postpartum participants with opioid use disorder (OUD), including medication for OUD (MOUD), and to increase provider capacity in the more rural reaches of the state. Through its MOM model Provider Incentive Program, the Department aims to not only provide an incentive to providers who obtain a DATA 2000 waiver, but also to encourage waivered prescribers to treat to capacity, with wraparound support from technical assistance opportunities with the Maryland Addiction Consultation Service and utilization of clinical tools developed by the state’s Prescription Drug Monitoring Program. Increasing office-based buprenorphine-dispensing locations offers an opportunity to destigmatize receiving treatment for OUD for those reluctant to seek MOUD in an opioid treatment program setting. Incorporating MOUD services into a primary care or OB/GYN setting removes stigma by normalizing MOUD treatment in a traditionally somatic health-focused setting. Pending the availability of MOM model funding, the MOM model Provider Incentive Program will incentivize 20 providers per year from 2021 through 2024.
For eligible provider types and regions, please refer to the MOM model Provider Incentive Program Letter of Intent Instructions (below).
The Department acknowledges the recent U.S. Department of Health and Human Services release of Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder that eliminates the requirement for physicians to complete DATA 2000 waiver training and allows physicians with this exemption to treat up to 30 patients. For the purposes of the MOM model Provider Incentive Program, eligible physician prescribers must complete 8 hours of training per current protocols and not seek an exemption.
General Notice – 2021 MOM Model Provider Incentive Program Open for Applications
The Maryland Department of Health (the Department) is accepting submissions for non-binding Letters of Intent (LOI) for the Provider Incentive Program funding opportunity. The Department will monitor progress of submissions to ensure completion. As an initiative of Maryland’s Maternal Opioid Misuse (MOM) model, the Department is offering reimbursement for undergoing DATA 2000 waiver to select provider types practicing in targeted jurisdictions to increase access to office-based buprenorphine in rural reaches of the state. Eligible provider types may submit LOIs for the Provider Incentive Program funding opportunity beginning January 1, 2021 and will have 90 days from the date the LOI is received to submit all materials to be eligible for $1,000 reimbursement of their time for obtaining a DATA 2000 waiver. The Department will accept twenty LOIs. Interested providers should carefully review the attestation form and LOI instructions available on the MOM model website. Please submit the Letter of Intent via email to firstname.lastname@example.org. LOIs will be accepted on a rolling basis until September 30, 2021, or as long as funds are available. This site will be updated once the submission limit has been reached for 2021.
This project is supported by the Centers for Medicare and Medicaid Services (CMS) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $3.6 million with 100 percent funded by CMS/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CMS/HHS, or the U.S. Government.